Epclusa
Epclusa is a pharmaceutical drug with 10 clinical trials. Currently 2 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
2
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Expanding the Pool in Lung Transplantation
Clinical Trials (10)
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Expanding the Pool in Lung Transplantation
Eliminating HCV Infection Among PWUD
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Micro-elimination of Hepatitis C Virus Infection in Uremics
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10